Immunoconjugates in the management of hairy cell leukemia

Best Practice and Research: Clinical Haematology

Volumn 28, Issue 4, 2015, Pages 236-245

  Kreitman, Robert J ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BL22; CD22; CD25; Moxetumomab pasudotox; Pseudomonas exotoxin; Recombinant immunotoxin

Indexed keywords

ANTIBODY CONJUGATE; CD22 ANTIGEN; IMMUNOTOXIN; IMMUNOTOXIN BL22; IMMUNOTOXIN LMB2; MOXETUMOMAB PASUDOTOX; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; B RAF KINASE; B3(FV)-PE38KDEL RECOMBINANT IMMUNOTOXIN; BACTERIAL TOXIN; BRAF PROTEIN, HUMAN; CLADRIBINE; ELONGATION FACTOR 2; EXOTOXIN; MONOCLONAL ANTIBODY; PENTOSTATIN;

ARTICLE; DRUG DOSE ESCALATION; DRUG USE; HAIRY CELL LEUKEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOGENICITY; INVESTIGATIVE PROCEDURES; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RISK FACTOR; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; LEUKEMIA, HAIRY CELL; MORTALITY; MUTATION; PATHOLOGY; REMISSION; SURVIVAL ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CLADRIBINE; CLINICAL TRIALS AS TOPIC; EXOTOXINS; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, HAIRY CELL; MUTATION; NEOPLASM, RESIDUAL; PENTOSTATIN; PEPTIDE ELONGATION FACTOR 2; PROTO-ONCOGENE PROTEINS B-RAF; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 84983174913     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2015.09.003     Document Type: Review

References (79)

1. B.A. Bouroncle, B.K. Wiseman, and C.A. Doan Leukemic reticuloendotheliosis Blood 13 1958 609 630
2. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics CA Cancer J Clin 2015 65 2015 5 29
3. M. Grever, K. Kopecky, M.K. Foucar, D. Head, J.M. Bennett, R.E. Hutchison, and et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study J Clin Oncol 13 1995 974 982
4. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, and et al. WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed. 2 2008 World Health Organization
5. E. Matutes, A. Wotherspoon, and D. Catovsky The variant form of hairy-cell leukaemia Best Pract Res Clin Haematol 16 2003 41 56
6. J.C. Cawley, G.F. Burns, and F.G. Hayhoe A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia Leuk Res 4 1980 547 559
7. T. Robak Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment Cancer Treat Rev 37 2011 3 10
8. H. Shao, K.R. Calvo, M. Grönborg, P.R. Tembhare, R.J. Kreitman, M. Stetler-Stevenson, and et al. JBB 2015
9. E. Matutes Immunophenotyping and differential diagnosis of hairy cell leukemia Hematol Oncol Clin North Am 20 2006 1051 1063
10. G. Venkataraman, C. Aguhar, R.J. Kreitman, C.M. Yuan, and M. Stetler-Stevenson JBB 2015
11. G.A. Jasper, I. Arun, D. Venzon, R.J. Kreitman, A.S. Wayne, C.M. Yuan, and et al. JBB 2015
12. R.W. Sharpe, and K.J. Bethel Hairy cell leukemia: diagnostic pathology Hematol Oncol Clin North Am 20 2006 1023 1049
13. E. Arons, T. Suntum, M. Stetler-Stevenson, and R.J. Kreitman JBB 2015
14. L. Xi, E. Arons, W. Navarro, K.R. Calvo, M. Stetler-Stevenson, M. Raffeld, and et al. JBB 2015
15. A. Saven, C. Burian, J.A. Koziol, and L.D. Piro Long-term follow-up of patients with hairy cell leukemia after cladribine treatment Blood 92 1998 1918 1926
16. R.J. Kreitman, W.H. Wilson, K. Bergeron, M. Raggio, M. Stetler-Stevenson, D.J. FitzGerald, and et al. JBB 2015
17. P. Chadha, A.W. Rademaker, P. Mendiratta, B. Kim, D.M. Evanchuk, D. Hakimian, and et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern university experience Blood 106 2005 241 246
18. L.D. Piro, C.J. Carrera, D.A. Carson, and E. Beutler Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine N Engl J Med 322 1990 1117 1121
19. A.S. Spiers, D. Moore, P.A. Cassileth, D.P. Harrington, F.J. Cummings, R.S. Neiman, and et al. Remissions in hairy-cell leukemia with pentostatin (2-deoxycoformycin) N Engl J Med 316 1987 825 830
20. G.R. Goodman, C. Burian, J.A. Koziol, and A. Saven Extended follow-up of patients with hairy cell leukemia after treatment with cladribine J Clin Oncol 21 2003 891 896
21. M. Else, C.E. Dearden, E. Matutes, J. Garcia-Talavera, A.Z. Rohatiner, S.A. Johnson, and et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis Br J Haematol 145 2009 733 740
22. I.W. Flinn, K.J. Kopecky, M.K. Foucar, D. Head, J.M. Bennett, R. Huchison, and et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin Blood 96 2000 2981 2986
23. J.D. Rosenberg, C. Burian, J. Waalen, and A. Saven Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series Blood 123 2014 177 183
24. H. Sawada, K. Nishii, T. Suzuki, K. Hasegawa, T. Hata, I. Nagatsu, and et al. Autonomic neuropathy in transgenic mice caused by immunotoxin targeting of the peripheral nervous system J Neurosci Res 51 1998 162 173
25. G.R. Goodman, E. Beutler, and A. Saven Cladribine in the treatment of hairy-cell leukaemia Best Pract Res Clin Haematol 16 2003 101 116
26. Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia Leukemia 1 1987 405
27. B.D. Cheson, J.M. Sorensen, D.A. Vena, M.J. Montello, J.A. Barrett, E. Damasio, and et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients J Clin Oncol 16 1998 3007 3015
28. R.J. Kreitman, W.H. Wilson, D. Robbins, I. Margulies, M. Stetler-Stevenson, T.A. Waldmann, and et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin Blood 94 1999 3340 3348
29. R.J. Kreitman, W.H. Wilson, J.D. White, M. Stetler-Stevenson, E.S. Jaffe, T.A. Waldmann, and et al. Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies J Clin Oncol 18 2000 1614 1636
30. R.J. Kreitman, D.R. Squires, M. Stetler-Stevenson, P. Noel, D.J. Fitzgerald, W.H. Wilson, and et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies J Clin Oncol 23 2005 6719 6729
31. R.J. Kreitman, M. Stetler-Stevenson, I. Margulies, P. Noel, D.J.P. FitzGerald, W.H. Wilson, and et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia J Clin Oncol 27 2009 2983 2990
32. R.J. Kreitman, M.S. Tallman, T. Robak, S. Coutre, W.H. Wilson, M. Stetler-Stevenson, and et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia J Clin Oncol 30 2012 1822 1828
33. R.J. Kreitman, W. Wilson, K.R. Calvo, E. Arons, L. Roth, J. Sapolsky, and et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia Clin Cancer Res 19 2013 6873 6881
34. M. Burotto, M. Stetler-Stevenson, E. Arons, H. Zhou, W. Wilson, and R.J. Kreitman Bendamustine and rituximab in relapsed and refractory hairy cell leukemia Clin Cancer Res 19 2013 6313 6321
35. E. Arons, I. Margulies, L. Sorbara, M. Raffeld, M. Stetler-Stevenson, I. Pastan, and et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction Clin Cancer Res 12 2006 2804 2811
36. D.J.P. FitzGerald, T.A. Waldmann, M.C. Willingham, and I. Pastan Pseudomonas exotoxin-Anti-Tac: cell specific immunotoxin active against cells expressing the human T cell growth factor receptor J Clin Invest 74 1984 966 971
37. M. Kronke, J.M. Depper, W.J. Leonard, E.S. Vitetta, T.A. Waldmann, and W.C. Green Adult T cell leukemia: a potential target for ricin A chain immunotoxins Blood 65 1985 1416 1421
38. I. Pastan, M.C. Willingham, and D.J. FitzGerald Immunotoxins Cell 47 1986 641 648
39. M. Yamaizumi, E. Mekada, T. Uchida, and Y. Okada One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell Cell 15 1978 245 250
40. Y. Endo, K. Mitsui, M. Motizuki, and K. Tsurugi The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes J Biol Chem 262 1987 5908 5912
41. S.F. Carroll, and R.J. Collier Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin J Biol Chem 262 1987 8707 8711
42. B.G. Van Ness, J.B. Howard, and J.W. Bodley ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products J Biol Chem 255 1980 10717-01720
43. H. Lorberboum-Galski, D. FitzGerald, V. Chaudhary, S. Adhya, and I. Pastan Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli Proc Natl Acad Sci U. S. A 85 1988 1922 1926
44. 389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins J Biol Chem 266 1991 21118 21124
45. R.J. Kreitman Getting plant toxins to fuse Leuk Res 21 1997 997 999
46. V.K. Chaudhary, C. Queen, R.P. Junghans, T.A. Waldmann, D.J. FitzGerald, and I. Pastan A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin Nature 339 1989 394 397
47. X. Du, R. Beers, D.J. FitzGerald, and I. Pastan Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity Cancer Res 68 2008 6300 6305
48. 280 generates the enzymatically active fragment which translocates to the cytosol J Biol Chem 267 1992 25396 25401
49. C. Fryling, M. Ogata, and D. FitzGerald Characterization of a cellular protease that cleaves Pseudomonas exotoxin Infect Immun 60 1992 497 502
50. M.F. Chiron, C.M. Fryling, and D.J. FitzGerald Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver J Biol Chem 269 1994 18167 18176
51. M.L. McKee, and D.J. FitzGerald Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story Biochemistry 38 1999 16507 16513
52. R.J. Kreitman, and I. Pastan Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor Biochem J 307 1995 29 37
53. C. Theuer, S. Kasturi, and I. Pastan Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes Biochemistry 33 1994 5894 5900
54. C.P. Theuer, J. Buchner, D. FitzGerald, and I. Pastan The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion Proc Natl Acad Sci U. S. A. 90 1993 7774 7778
55. T.R. Webb, S.H. Cross, L. McKie, R. Edgar, L. Vizor, J. Harrison, and et al. Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development J Cell Sci 121 2008 3140 3145
56. U. Brinkmann, E. Brinkmann, M. Gallo, and I. Pastan Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1 Proc Natl Acad Sci U. S. A. 92 1995 10427 10431
57. I.J.C. Keppler-Hafkemeyer, R.J. Kreitman, and I. Pastan Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies Int J Cancer 87 2000 86 94
58. T. Decker, M. Oelsner, R.J. Kreitman, G. Salvatore, Q.C. Wang, I. Pastan, and et al. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia cells by anti-CD22 immunotoxins Blood 103 2004 2718 2726
59. X. Du, R.J. Youle, D.J. FitzGerald, and I. Pastan Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1 Mol Cell Biol 30 2010 3444 3452
60. R.J. Kreitman, J.K. Batra, S. Seetharam, V.K. Chaudhary, D.J. FitzGerald, and I. Pastan Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds Bioconj Chem 4 1993 112 120
61. R.J. Kreitman, V.K. Chaudhary, R.W. Kozak, D.J.P. FitzGerald, T.A. Waldmann, and I. Pastan Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia Blood 80 1992 2344 2352
62. R.J. Kreitman, V.K. Chaudhary, T.A. Waldmann, B. Hanchard, B. Cranston, D.J.P. FitzGerald, and et al. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia Leukemia 7 1993 553 562
63. T. Saito, R.J. Kreitman, S-i. Hanada, T. Makino, A. Utsunomiya, T. Sumizawa, and et al. Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor Cancer Res 54 1994 1059 1064
64. D.H. Robbins, I. Margulies, M. Stetler-Stevenson, and R.J. Kreitman Hairy cell leukemia, a B-cell neoplasm which is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2) Clin Cancer Res 6 2000 693 700
65. I. Cordone, L. Annino, S. Masi, E. Pescarmona, S. Rahimi, A. Ferrari, and et al. Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia J Clin Pathol 48 1995 955 960
66. B.A. Robbins, D.J. Ellison, J.C. Spinosa, C.A. Carey, R.J. Lukes, S. Poppema, and et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia Blood 82 1993 1277 1287
67. R.J. Kreitman, H.J. Hansen, A.L. Jones, D.J.P. FitzGerald, D.M. Goldenberg, and I. Pastan Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice Cancer Res 53 1993 819 825
68. E. Mansfield, I. Pastan, and D.J. FitzGerald Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies Bioconj Chem 7 1996 557 563
69. E. Mansfield, M.F. Chiron, P. Amlot, I. Pastan, and D.J. FitzGerald Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells Biochem Soc Trans 25 1997 709 714
70. E. Mansfield, P. Amlot, I. Pastan, and D.J. FitzGerald Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors Blood 90 1997 2020 2026
71. Y. Reiter, U. Brinkmann, R.J. Kreitman, S.-H. Jung, B. Lee, and I. Pastan Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions Biochemistry 33 1994 5451 5459
72. R.J. Kreitman, I. Margulies, M. Stetler-Stevenson, Q.C. Wang, D.J.P. FitzGerald, and I. Pastan Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias Clin Cancer Res 6 2000 1476 1487
73. R.J. Kreitman, Q.C. Wang, D.J.P. FitzGerald, and I. Pastan Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys Int J Cancer 81 1999 148 155
74. R. Baluna, and E.S. Vitetta Vascular leak syndrome: a side effect of immunotherapy Immunopharmacology 37 1997 117 132
75. G. Salvatore, R. Beers, I. Margulies, R.J. Kreitman, and I. Pastan Improved cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display Clin Cancer Res 8 2002 995 1002
76. R.F. Alderson, R.J. Kreitman, T. Chen, P. Yeung, R. Herbst, J.A. Fox, and et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies Clin Cancer Res 15 2009 832 839
77. T.K. Bera, M. Onda, R.J. Kreitman, and I. Pastan An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies Leuk Res 38 2014 1224 1229
78. R. Mazor, J. Eberle, X. Hu, A.N. Vassall, M. Onda, R. Beers, and et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes Proc Natl Acad Sci U. S. A. 111 2014 8571 8576
79. J.L. Hessler, and R.J. Kreitman An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor Biochemistry 36 1997 14577 14582